drugset / Trial / NCT00982267
A Trial Of SU14813 In Patients With Advanced Solid Malignancies
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to define the Maximum tolerated dose of SU14813 when administered as single agent in patients with solid tumors.
Timeline
- Start
- 2003-12
- Primary completion
- 2008-11
- Completion
- 2011-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SU014813 | Small molecule | 50 mg | Oral |
| Subject | SU014813 | Small molecule | 100 mg | Oral |
| Subject | SU014813 | Small molecule | 200 mg | Oral |
| Subject | SU014813 | Small molecule | 250 mg | Oral |